Carlos A. Gongora

Carlos A. Gongora

Auto-generated profile, based on publicly available information

Carlos A. Gongora

Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine , 111 E 210th St, Bronx, NY 10467

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
CGCarlos A. Gongora
Carlos A. Gongora
ZDZsofia D. Drobni
Zsofia D. Drobni
TSThiago Quinaglia Araujo Costa Silva
Thiago Quinaglia Araujo Costa Silva
AZAmna Zafar
Amna Zafar
JGJingyi Gong
Jingyi Gong
TNTomas G. Neilan
Tomas G. Neilan

1 July 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CGCarlos A. Gongora
Carlos A. Gongora
MSMasahiko Shibuya
Masahiko Shibuya
JWJeffrey D. Wessler
Jeffrey D. Wessler
JMJenn McGregor
Jenn McGregor
ATArmando Tellez
Armando Tellez
JGJuan F. Granada
Juan F. Granada

1 December 2013 in Translational Research
Verified
Journal Article
Closed access
ATArmando Tellez
Armando Tellez
SRSerge Rousselle
Serge Rousselle
TPTaylor Palmieri
Taylor Palmieri
WRWilliam R. Rate
William R. Rate
JWJoan Wicks
Joan Wicks
JGJuan F. Granada
Juan F. Granada

20 December 2022 in JACC: Cardiooncology
Verified
Journal Article
Open access
CLCharlotte Lee
Charlotte Lee
ZDZsofia D. Drobni
Zsofia D. Drobni
AZAmna Zafar
Amna Zafar
CGCarlos A. Gongora
Carlos A. Gongora
DZDaniel A. Zlotoff
Daniel A. Zlotoff
TNTomas G. Neilan
Tomas G. Neilan
The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular (CV) events, and patients with pre-existing autoimmune disease are at increased CV risk. The aim of this study was to characterize the risk for CV events in patients with pre-existing autoimmune disease post-ICI. This was a retrospective study of 6,683 patients treated with ICIs within an academic network. Autoimmune disease prior to ICI was confirmed by chart review. Baseline characteristics and risk for CV and non-CV immune-related adverse events were compared with a matched control group (1:1 ratio) of ICI patients without autoimmune disease. Matching was based on age, sex, history of coronary artery disease, history of heart failure, and diabetes mellitus. CV events were a composite of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, or myocarditis. Univariable and multivariable Cox proportional hazards models were used to determine the association between autoimmune disease and CV events. Among 502 patients treated with ICIs, 251 patients with and 251 patients without autoimmune disease were studied. During a median follow-up period of 205 days, there were 45 CV events among patients with autoimmune disease and 22 CV events among control subjects (adjusted HR: 1.77; 95% CI: 1.04-3.03; P = 0.0364). Of the non-CV immune-related adverse events, there were increased rates of psoriasis (11.2% vs 0.4%; P < 0.001) and colitis (24.3% vs 16.7%; P = 0.045) in patients with autoimmune disease. Patients with autoimmune disease have an increased risk for CV and non-CV events post-ICI.

14 September 2022 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
TQThiago Quinaglia
Thiago Quinaglia
CGCarlos Gongora
Carlos Gongora
MAMagid Awadalla
Magid Awadalla
MHMalek Hassan
Malek Hassan
AZAmna Zafar
Amna Zafar
TNTomas G. Neilan
Tomas G. Neilan

7 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AZAmna Zafar
Amna Zafar
ZDZsofia D. Drobni
Zsofia D. Drobni
MLMatthew Lei
Matthew Lei
CGCarlos A. Gongora
Carlos A. Gongora
TQThiago Quinaglia
Thiago Quinaglia
TNTomas G. Neilan
Tomas G. Neilan
Background: Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the safety and efficacy of re-challenge with 5-FU after pre-treatment with calcium channel blockers (CCBs) and long-acting nitrates among patients 5-FU associated coronary vasospasm. Methods: We conducted a retrospective study of patients with 5-FU coronary vasospasm at a single academic center. By protocol, those referred to cardio-oncology received pre-treatment with either combination [nitrates and CCBs] or single-agent therapy [nitrates or CCBs]) prior to re-challenge with 5-FU. Our primary outcome was overall survival. Other important outcomes included progression-free survival and safety. Results: Among 6,606 patients who received 5-FU from January 2001 to Dec 2020, 115 (1.74%) developed coronary vasospasm. Of these 115 patients, 81 patients continued 5-FU therapy, while 34 stopped. Of the 81 who continued, 78 were referred to cardio-oncology and prescribed CCBs and/or nitrates prior to subsequent 5-FU, while the remaining 3 continued 5-FU without cardiac pre-treatment. Of the 78, 56.4% (44/78) received both nitrates and CCBs, 19.2% (15/78) received CCBs alone, and 24.4% (19/78) received nitrates alone. When compared to patients who stopped 5-FU, those who continued 5-FU after pre-treatment (single or combination therapy) had a decreased risk of death (HR 0.42, P = 0.005 [95% CI 0.23–0.77]) and a trend towards decreased cancer progression (HR 0.60, P = 0.08 [95% CI 0.34–1.06]). No patient in the pre-treatment group had a myocardial infarct after re-challenge; however, chest pain (without myocardial infarction) recurred in 19.2% (15/78) among those who received cardiac pre-treatment vs. 66.7% (2/3) among those who did not (P = 0.048). There was no difference in efficacy or the recurrence of vasospasm among patients who received pre-treatment with a single agent (nitrates or CCBs) or combination therapy (14.7% (5/34) vs. 25.0% (11/44), P = 0.26). Conclusion: Re-challenge after pre-treatment with CCBs and nitrates guided by a cardio-oncology service was safe and allowed continued 5-FU therapy.